Cargando…
Recombinant single-cycle influenza virus with exchangeable pseudotypes allows repeated immunization to augment anti-tumour immunity with immune checkpoint inhibitors
Virus-based tumour vaccines offer many advantages compared to other antigen-delivering systems. They generate concerted innate and adaptive immune response, and robust CD8(+) T cell responses. We engineered a non-replicating pseudotyped influenza virus (S-FLU) to deliver the well-known cancer testis...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
eLife Sciences Publications, Ltd
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9831609/ https://www.ncbi.nlm.nih.gov/pubmed/36626205 http://dx.doi.org/10.7554/eLife.76414 |
_version_ | 1784867880108556288 |
---|---|
author | Kandasamy, Matheswaran Gileadi, Uzi Rijal, Pramila Tan, Tiong Kit Lee, Lian N Chen, Jili Prota, Gennaro Klenerman, Paul Townsend, Alain Cerundolo, Vincenzo |
author_facet | Kandasamy, Matheswaran Gileadi, Uzi Rijal, Pramila Tan, Tiong Kit Lee, Lian N Chen, Jili Prota, Gennaro Klenerman, Paul Townsend, Alain Cerundolo, Vincenzo |
author_sort | Kandasamy, Matheswaran |
collection | PubMed |
description | Virus-based tumour vaccines offer many advantages compared to other antigen-delivering systems. They generate concerted innate and adaptive immune response, and robust CD8(+) T cell responses. We engineered a non-replicating pseudotyped influenza virus (S-FLU) to deliver the well-known cancer testis antigen, NY-ESO-1 (NY-ESO-1 S-FLU). Intranasal or intramuscular immunization of NY-ESO-1 S-FLU virus in mice elicited a strong NY-ESO-1-specific CD8(+) T cell response in lungs and spleen that resulted in the regression of NY-ESO-1-expressing lung tumour and subcutaneous tumour, respectively. Combined administration with anti-PD-1 antibody, NY-ESO-1 S-FLU virus augmented the tumour protection by reducing the tumour metastasis. We propose that the antigen delivery through S-FLU is highly efficient in inducing antigen-specific CD8(+) T cell response and protection against tumour development in combination with PD-1 blockade. |
format | Online Article Text |
id | pubmed-9831609 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | eLife Sciences Publications, Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-98316092023-01-11 Recombinant single-cycle influenza virus with exchangeable pseudotypes allows repeated immunization to augment anti-tumour immunity with immune checkpoint inhibitors Kandasamy, Matheswaran Gileadi, Uzi Rijal, Pramila Tan, Tiong Kit Lee, Lian N Chen, Jili Prota, Gennaro Klenerman, Paul Townsend, Alain Cerundolo, Vincenzo eLife Cancer Biology Virus-based tumour vaccines offer many advantages compared to other antigen-delivering systems. They generate concerted innate and adaptive immune response, and robust CD8(+) T cell responses. We engineered a non-replicating pseudotyped influenza virus (S-FLU) to deliver the well-known cancer testis antigen, NY-ESO-1 (NY-ESO-1 S-FLU). Intranasal or intramuscular immunization of NY-ESO-1 S-FLU virus in mice elicited a strong NY-ESO-1-specific CD8(+) T cell response in lungs and spleen that resulted in the regression of NY-ESO-1-expressing lung tumour and subcutaneous tumour, respectively. Combined administration with anti-PD-1 antibody, NY-ESO-1 S-FLU virus augmented the tumour protection by reducing the tumour metastasis. We propose that the antigen delivery through S-FLU is highly efficient in inducing antigen-specific CD8(+) T cell response and protection against tumour development in combination with PD-1 blockade. eLife Sciences Publications, Ltd 2023-01-10 /pmc/articles/PMC9831609/ /pubmed/36626205 http://dx.doi.org/10.7554/eLife.76414 Text en © 2023, Kandasamy et al https://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Cancer Biology Kandasamy, Matheswaran Gileadi, Uzi Rijal, Pramila Tan, Tiong Kit Lee, Lian N Chen, Jili Prota, Gennaro Klenerman, Paul Townsend, Alain Cerundolo, Vincenzo Recombinant single-cycle influenza virus with exchangeable pseudotypes allows repeated immunization to augment anti-tumour immunity with immune checkpoint inhibitors |
title | Recombinant single-cycle influenza virus with exchangeable pseudotypes allows repeated immunization to augment anti-tumour immunity with immune checkpoint inhibitors |
title_full | Recombinant single-cycle influenza virus with exchangeable pseudotypes allows repeated immunization to augment anti-tumour immunity with immune checkpoint inhibitors |
title_fullStr | Recombinant single-cycle influenza virus with exchangeable pseudotypes allows repeated immunization to augment anti-tumour immunity with immune checkpoint inhibitors |
title_full_unstemmed | Recombinant single-cycle influenza virus with exchangeable pseudotypes allows repeated immunization to augment anti-tumour immunity with immune checkpoint inhibitors |
title_short | Recombinant single-cycle influenza virus with exchangeable pseudotypes allows repeated immunization to augment anti-tumour immunity with immune checkpoint inhibitors |
title_sort | recombinant single-cycle influenza virus with exchangeable pseudotypes allows repeated immunization to augment anti-tumour immunity with immune checkpoint inhibitors |
topic | Cancer Biology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9831609/ https://www.ncbi.nlm.nih.gov/pubmed/36626205 http://dx.doi.org/10.7554/eLife.76414 |
work_keys_str_mv | AT kandasamymatheswaran recombinantsinglecycleinfluenzaviruswithexchangeablepseudotypesallowsrepeatedimmunizationtoaugmentantitumourimmunitywithimmunecheckpointinhibitors AT gileadiuzi recombinantsinglecycleinfluenzaviruswithexchangeablepseudotypesallowsrepeatedimmunizationtoaugmentantitumourimmunitywithimmunecheckpointinhibitors AT rijalpramila recombinantsinglecycleinfluenzaviruswithexchangeablepseudotypesallowsrepeatedimmunizationtoaugmentantitumourimmunitywithimmunecheckpointinhibitors AT tantiongkit recombinantsinglecycleinfluenzaviruswithexchangeablepseudotypesallowsrepeatedimmunizationtoaugmentantitumourimmunitywithimmunecheckpointinhibitors AT leeliann recombinantsinglecycleinfluenzaviruswithexchangeablepseudotypesallowsrepeatedimmunizationtoaugmentantitumourimmunitywithimmunecheckpointinhibitors AT chenjili recombinantsinglecycleinfluenzaviruswithexchangeablepseudotypesallowsrepeatedimmunizationtoaugmentantitumourimmunitywithimmunecheckpointinhibitors AT protagennaro recombinantsinglecycleinfluenzaviruswithexchangeablepseudotypesallowsrepeatedimmunizationtoaugmentantitumourimmunitywithimmunecheckpointinhibitors AT klenermanpaul recombinantsinglecycleinfluenzaviruswithexchangeablepseudotypesallowsrepeatedimmunizationtoaugmentantitumourimmunitywithimmunecheckpointinhibitors AT townsendalain recombinantsinglecycleinfluenzaviruswithexchangeablepseudotypesallowsrepeatedimmunizationtoaugmentantitumourimmunitywithimmunecheckpointinhibitors AT cerundolovincenzo recombinantsinglecycleinfluenzaviruswithexchangeablepseudotypesallowsrepeatedimmunizationtoaugmentantitumourimmunitywithimmunecheckpointinhibitors |